Clinical Trials / Research Studies

Neurofibromatosis Sarcoma MPNST Relapse / Refractory

Brain and Spinal Tumors Research Studies

< Back to Young Adult Cancer Research Studies Page

Neurofibromatosis Sarcoma MPNST Relapse / Refractory

APEC1621: Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders

  • Ages: 12 Months to 21 Years

PURPOSE: This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/o ...More

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)

  • Ages: From 18 to 99 years old

PURPOSE: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Open treatment arms: See ...More

FLASH: Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases

  • Ages: 18 Years and older

This clinical investigation is designed to assess the workflow feasibility of FLASH radiotherapy treatment in a clinical setting, as well as the toxicities, and pain relief when used to treat bone metastasis(-es) in the extremities (excluding feet, hands, wrists). FLASH radiotherapy has been shown i ...More

LOXO-RET-18036: A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

  • Ages: 6 Months to 21 Years  

To determine the safety of oral LOXO-292 in pediatric patients with advanced solid tumors: Dose limiting toxicities (DLTs) [ Time Frame: During the first 28-day cycle of LOXO-292 treatment ] LOXO-RET-18036: A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patient ...More

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (DeFi)

  • Ages: 18 years or older

The primary goal is to evaluate nirogacestat in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). Half of the participants will receive nirogacestat while the other half will receive placebo. NIR-DT-301: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Vers ...More

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  • Ages: 2 Years to 20 Years

This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. The main purpose of this study is to evaluate the safety of palbociclib in combination with chemotherapy in order t ...More